Autifony Therapeutics Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
28
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$770M
- Investors
-
1
Autifony Therapeutics General Information
Description
Developer of a drug discovery platform focused on ion channel modulators designed to treat disorders of the central nervous system. The company offers deep expertise in ion channel biology and drug development, enabling the treatment of rare neurodevelopmental disorders like Dravet Syndrome and Fragile X Syndrome, as well as broader indications such as schizophrenia and Alzheimer's disease.
Contact Information
Website
www.autifony.com(Operating Subsidiary)
Corporate Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road, Hertfordshire
- Stevenage SG1 2FX
- England, United Kingdom
Corporate Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road, Hertfordshire
- Stevenage SG1 2FX
- England, United Kingdom
Autifony Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 14-Nov-2023 | $770M | Completed | Clinical Trials - Phase 2 | ||
| 11. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 10. Later Stage VC | 18-Dec-2017 | Completed | Clinical Trials - Phase 2 | |||
| 9. Later Stage VC | 15-Mar-2017 | Completed | Clinical Trials - Phase 2 | |||
| 8. Early Stage VC (Series A3) | 10-Jul-2015 | Completed | Clinical Trials - Phase 2 | |||
| 7. Grant | 01-Jul-2015 | Completed | Clinical Trials - Phase 2 | |||
| 6. Grant | 04-Jun-2014 | Completed | Clinical Trials - Phase 2 | |||
| 5. Early Stage VC (Series A2) | 29-Oct-2013 | Completed | Clinical Trials - Phase 2 | |||
| 4. Grant | 01-Jul-2013 | $2.01M | $12.5M | Completed | Clinical Trials - Phase 2 | |
| 3. Early Stage VC (Series A) | 29-Apr-2013 | $11M | $12.5M | Completed | Clinical Trials - Phase 2 |
Autifony Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Series A3 NZ | ||||||||
| Series A3 | ||||||||
| Series A2 NV | ||||||||
| Series A2 | 1,698,418 | $0.001555 | $1.87 | $1.87 | 1x | $1.87 | 6.41% | |
| Series A | 8,125,000 | $0.001555 | $1.55 | $1.55 | 1x | $1.55 | 30.66% |
Autifony Therapeutics Comparisons
Industry
Financing
Details
Autifony Therapeutics Competitors (25)
One of Autifony Therapeutics’s 25 competitors is Oligomerix, a Venture Capital-Backed company based in Bronx, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Oligomerix | Venture Capital-Backed | Bronx, NY | ||||
| Contineum Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Lite Strategy | Corporation | San Diego, CA |
Autifony Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Autifony Therapeutics Patents
Autifony Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026093398-A1 | Kv3 modulators for use in the treatment or prophylaxis of amyotrophic lateral sclerosis (als) | Pending | 29-Oct-2024 | ||
| EP-4630117-A1 | Compounds for the treatment of centra nervous system disorders | Pending | 06-Dec-2022 | ||
| US-20260199309-A1 | Compounds for the treatment of centra nervous system disorders | Pending | 06-Dec-2022 | ||
| WO-2024121552-A1 | Compounds for the treatment of centra nervous system disorders | Inactive | 06-Dec-2022 | ||
| AU-2022327657-A1 | Potassium channel modulators | Pending | 10-Aug-2021 | C07D471/04 |
Autifony Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Autifony Therapeutics Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Boehringer Ingelheim | Corporation | Minority | ||
| GSK | Corporation | Minority | ||
| IP Group | Venture Capital | Minority | ||
| Innovate UK | Government | Minority | ||
| International Biotechnology Trust | Venture Capital | Minority |
Autifony Therapeutics FAQs
-
When was Autifony Therapeutics founded?
Autifony Therapeutics was founded in 2011.
-
Where is Autifony Therapeutics headquartered?
Autifony Therapeutics is headquartered in Stevenage, United Kingdom.
-
What is the size of Autifony Therapeutics?
Autifony Therapeutics has 28 total employees.
-
What industry is Autifony Therapeutics in?
Autifony Therapeutics’s primary industry is Drug Discovery.
-
Is Autifony Therapeutics a private or public company?
Autifony Therapeutics is a Private company.
-
What is the current valuation of Autifony Therapeutics?
The current valuation of Autifony Therapeutics is .
-
What is Autifony Therapeutics’s current revenue?
The current revenue for Autifony Therapeutics is .
-
How much funding has Autifony Therapeutics raised over time?
Autifony Therapeutics has raised $82.6M.
-
Who are Autifony Therapeutics’s investors?
Boehringer Ingelheim, GSK, IP Group, Innovate UK, and International Biotechnology Trust are 5 of 10 investors who have invested in Autifony Therapeutics.
-
Who are Autifony Therapeutics’s competitors?
Oligomerix, Contineum Therapeutics, Aclaris Therapeutics, Neurona Therapeutics, and Lite Strategy are some of the 25 competitors of Autifony Therapeutics.
-
When was Autifony Therapeutics acquired?
Autifony Therapeutics was acquired on 14-Nov-2023.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
